Creatv Bio, a division of Creatv MicroTech Inc, a liquid biopsy company focused on innovative diagnostics for cancer, and Neovia Oncology LLC, a pharmaceutical company developing novel oncology therapies, announced on Tuesday the signing of a strategic partnership agreement to collaborate on Neovia's upcoming studies treating patients with advanced multiple drug-resistant solid tumours who are entering late lines of therapy.

This collaboration is expected to generate translational and biomarker data designed to improve patient stratification and deepen understanding of treatment response dynamics in advanced cancers.

In addition to its development as a systemic therapy, Neovia is also evaluating the broader platform potential of Neovia's investigational candidate NEV-801 in next-generation oncology applications, including antibody-drug conjugate (ADC) strategies.

Creatv's LifeTracDx blood test isolates Cancer Associated Macrophage-Like Cells (CAMLs) and Circulating Tumour Cells (CTCs) using Creatv's CellSieve microfilters to develop companion diagnostics to monitor drug targets and provide information on patient treatment response.